As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...

The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

HCV—can persist in the livers of those infected and even lead to liver disease or failure in extreme cases. It affects tens ...

Hep C treatment challenges may include overcoming stigma, managing side effects, and coping with financial costs. But support is available. If you’ve received a hepatitis C diagnosis, it’s important ...

A new treatment for hepatitis C that costs just $300 has been found to deliver a cure rate of more than 97 percent, making it equal to or more effective than existing treatments that run into the tens ...

A combination treatment involving tobevibart and elebsiran significantly improved disease activity in adults with chronic ...

SAN FRANCISCO — An 8-week regimen of the combination of glecaprevir plus pibrentasvir (Mavyret, AbbVie) can eliminate most genotypes of the hepatitis C virus in treatment-naïve patients with ...

Tapestry Health is a key partner in a new, $12-million Brown University five-year study of drug use and barriers to health care services, like HIV and hepatitis C treatment and overdose prevention.

Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...

Even with insurers reluctant to pay, Sovaldi prescriptions have eclipsed those for all other hepatitis C pills combined in a matter of months, new data from IMS Health indicate. The promise of a real ...

Chronic hepatitis C infection has been linked to a higher risk of pancreatic cancer. Learn more about findings from a major ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...